Direct antiviral therapy for treatment of hepatitis C : a real-world study from Brazil

Introduction and objectives Direct antiviral agents (DAAs) including sofosbuvir (SOF), daclatasvir (DCV), simeprevir (SIM) and ombitasvir, paritaprevir and dasabuvir were introduced 2015 in Brazil for treatment of hepatitis C virus (HCV) infection. The aims of this study were to assess effectiveness...

Descripción completa

Detalles Bibliográficos
Autores: Lobato, Cirley Maria de Oliveira, Cheinquer, Hugo, Bittencourt, Paulo Lisboa
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2019
País:Brasil
Institución:Universidade Federal do Rio Grande do Sul (UFRGS)
Repositorio:Repositório Institucional da UFRGS
Idioma:inglés
OAI Identifier:oai:www.lume.ufrgs.br:10183/216695
Acceso en línea:http://hdl.handle.net/10183/216695
Access Level:acceso abierto
Palabra clave:Hepatite C crônica
Antivirais
Cirrose hepática
Chronic hepatitis C
Direct antiviral agents
Hepatic fibrosis
Cirrhosis
id BR_d6864ef4f4e06dfeb97e358050c352ba
oai_identifier_str oai:www.lume.ufrgs.br:10183/216695
network_acronym_str BR
network_name_str Brasil
repository_id_str
spelling 2020-12-18T04:13:34Z20191665-2681http://hdl.handle.net/10183/216695001119768Introduction and objectives Direct antiviral agents (DAAs) including sofosbuvir (SOF), daclatasvir (DCV), simeprevir (SIM) and ombitasvir, paritaprevir and dasabuvir were introduced 2015 in Brazil for treatment of hepatitis C virus (HCV) infection. The aims of this study were to assess effectiveness and safety of HCV treatment with DAA in real-life world in a highly admixed population from Brazil. Materials and methods All Brazilian reference centers for HCV treatment were invited to take part in a web-based registry, prospectively conducted by the Brazilian Society of Hepatology, to assess outcomes of HCV treatment in Brazil with DAAs. Data to be collected included demographics, disease severity and comorbidities, genotype (GT), viral load, DAA regimens, treatment side effects and sustained virological response (SVR). Results 3939 patients (60% males, mean age 58 ± 10 years) throughout the country were evaluated. Most had advanced fibrosis or cirrhosis, GT1 and were treated with SOF/DCV or SOF/SIM. Overall SVR rates were higher than 95%. Subjects with decompensated cirrhosis, GT2 and GT3 have lower SVR rates of 85%, 90% and 91%, respectively. Cirrhosis and decompensated cirrhosis in GT1 and male sex and decompensated cirrhosis in GT3 were significantly associated with no SVR. Adverse events (AD) and serious AD occurred in 18% and 5% of those subjects, respectively, but less than 1% of patients required treatment discontinuation. Conclusion SOF-based DAA regimens are effective and safe in the heterogeneous highly admixed Brazilian population and could remain an option for HCV treatment at least in low-income countries.application/pdfengAnnals of hepatology. México. Vol. 18, no. 6 (2019), p. 849-854Hepatite C crônicaAntiviraisCirrose hepáticaChronic hepatitis CDirect antiviral agentsHepatic fibrosisCirrhosisDirect antiviral therapy for treatment of hepatitis C : a real-world study from BrazilEstrangeiroinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFRGSinstname:Universidade Federal do Rio Grande do Sul (UFRGS)instacron:UFRGSLobato, Cirley Maria de OliveiraCheinquer, HugoBittencourt, Paulo LisboaTEXT001119768.pdf.txt001119768.pdf.txtExtracted Texttext/plain32519http://www.lume.ufrgs.br/bitstream/10183/216695/2/001119768.pdf.txt369bc75ae93cda2336f488c035c4c6fdMD52ORIGINAL001119768.pdfTexto completo (inglês)application/pdf895298http://www.lume.ufrgs.br/bitstream/10183/216695/1/001119768.pdf7f2c750d582d1e3e80230ffe765a9270MD5110183/2166952020-12-19 05:19:31.430175oai:www.lume.ufrgs.br:10183/216695Repositório InstitucionalPUBhttps://lume.ufrgs.br/oai/requestlume@ufrgs.bropendoar:2020-12-19T07:19:31Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS)false
dc.title.pt_BR.fl_str_mv Direct antiviral therapy for treatment of hepatitis C : a real-world study from Brazil
title Direct antiviral therapy for treatment of hepatitis C : a real-world study from Brazil
spellingShingle Direct antiviral therapy for treatment of hepatitis C : a real-world study from Brazil
Lobato, Cirley Maria de Oliveira
Hepatite C crônica
Antivirais
Cirrose hepática
Chronic hepatitis C
Direct antiviral agents
Hepatic fibrosis
Cirrhosis
title_short Direct antiviral therapy for treatment of hepatitis C : a real-world study from Brazil
title_full Direct antiviral therapy for treatment of hepatitis C : a real-world study from Brazil
title_fullStr Direct antiviral therapy for treatment of hepatitis C : a real-world study from Brazil
title_full_unstemmed Direct antiviral therapy for treatment of hepatitis C : a real-world study from Brazil
title_sort Direct antiviral therapy for treatment of hepatitis C : a real-world study from Brazil
dc.creator.none.fl_str_mv Lobato, Cirley Maria de Oliveira
Cheinquer, Hugo
Bittencourt, Paulo Lisboa
author Lobato, Cirley Maria de Oliveira
author_facet Lobato, Cirley Maria de Oliveira
Cheinquer, Hugo
Bittencourt, Paulo Lisboa
author_role author
author2 Cheinquer, Hugo
Bittencourt, Paulo Lisboa
author2_role author
author
dc.subject.por.fl_str_mv Hepatite C crônica
Antivirais
Cirrose hepática
topic Hepatite C crônica
Antivirais
Cirrose hepática
Chronic hepatitis C
Direct antiviral agents
Hepatic fibrosis
Cirrhosis
dc.subject.eng.fl_str_mv Chronic hepatitis C
Direct antiviral agents
Hepatic fibrosis
Cirrhosis
description Introduction and objectives Direct antiviral agents (DAAs) including sofosbuvir (SOF), daclatasvir (DCV), simeprevir (SIM) and ombitasvir, paritaprevir and dasabuvir were introduced 2015 in Brazil for treatment of hepatitis C virus (HCV) infection. The aims of this study were to assess effectiveness and safety of HCV treatment with DAA in real-life world in a highly admixed population from Brazil. Materials and methods All Brazilian reference centers for HCV treatment were invited to take part in a web-based registry, prospectively conducted by the Brazilian Society of Hepatology, to assess outcomes of HCV treatment in Brazil with DAAs. Data to be collected included demographics, disease severity and comorbidities, genotype (GT), viral load, DAA regimens, treatment side effects and sustained virological response (SVR). Results 3939 patients (60% males, mean age 58 ± 10 years) throughout the country were evaluated. Most had advanced fibrosis or cirrhosis, GT1 and were treated with SOF/DCV or SOF/SIM. Overall SVR rates were higher than 95%. Subjects with decompensated cirrhosis, GT2 and GT3 have lower SVR rates of 85%, 90% and 91%, respectively. Cirrhosis and decompensated cirrhosis in GT1 and male sex and decompensated cirrhosis in GT3 were significantly associated with no SVR. Adverse events (AD) and serious AD occurred in 18% and 5% of those subjects, respectively, but less than 1% of patients required treatment discontinuation. Conclusion SOF-based DAA regimens are effective and safe in the heterogeneous highly admixed Brazilian population and could remain an option for HCV treatment at least in low-income countries.
publishDate 2019
dc.date.issued.fl_str_mv 2019
dc.date.accessioned.fl_str_mv 2020-12-18T04:13:34Z
dc.type.driver.fl_str_mv Estrangeiro
info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10183/216695
dc.identifier.issn.pt_BR.fl_str_mv 1665-2681
dc.identifier.nrb.pt_BR.fl_str_mv 001119768
identifier_str_mv 1665-2681
001119768
url http://hdl.handle.net/10183/216695
dc.language.iso.fl_str_mv eng
language eng
dc.relation.ispartof.pt_BR.fl_str_mv Annals of hepatology. México. Vol. 18, no. 6 (2019), p. 849-854
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Repositório Institucional da UFRGS
instname:Universidade Federal do Rio Grande do Sul (UFRGS)
instacron:UFRGS
instname_str Universidade Federal do Rio Grande do Sul (UFRGS)
instacron_str UFRGS
institution UFRGS
reponame_str Repositório Institucional da UFRGS
collection Repositório Institucional da UFRGS
bitstream.url.fl_str_mv http://www.lume.ufrgs.br/bitstream/10183/216695/2/001119768.pdf.txt
http://www.lume.ufrgs.br/bitstream/10183/216695/1/001119768.pdf
bitstream.checksum.fl_str_mv 369bc75ae93cda2336f488c035c4c6fd
7f2c750d582d1e3e80230ffe765a9270
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
repository.name.fl_str_mv Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS)
repository.mail.fl_str_mv lume@ufrgs.br
_version_ 1853675858109136896
score 15,300719

Similares en LA Referencia